**Claims**

1. A crystalline form of (*S*)-4-(2,2-difluoro-7-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-7-azaspiro[3.5]nonan-6-yl)benzoic acid.

2. The crystalline form of claim 1, wherein the crystalline form is Form A, and wherein the XRPD pattern has peaks (± 0.2 degrees 2θ) at 10.7, 20.5, and 18.8.

3. The crystalline form of claim 1, wherein the crystalline form is Form A, and wherein the XRPD pattern has peaks (± 0.2 degrees 2θ) at 10.7, 20.5, 18.8, and 21.7.

4. The crystalline form of claim 1, wherein the crystalline form is Form A, and wherein the XRPD pattern has peaks (± 0.2 degrees 2θ) at 10.7, 20.5, 18.8, 21.7, 19.6, 19.8, 12.5, 21.1, 23.3, 22.5, 27.3, and 15.5.

5. The crystalline form of any one of claims 1-4, wherein the crystalline form is Form A having a thermogravimetric analysis (TGA) curve characterized by a weight loss of about 0.51% at 150 °C when heated from 30°C and 300°C at 10 K/min.

6. The crystalline form of claim 1, wherein the (*S*)-4-(2,2-difluoro-7-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-7-azaspiro[3.5]nonan-6-yl)benzoic acid is in a free form, and further wherein the free form is an anhydrate form.

7. A crystalline *p*-toluene sulfonic acid salt form of (*S*)-4-(2,2-difluoro-7-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-7-azaspiro[3.5]nonan-6-yl)benzoic acid.

8. The crystalline form of claim 7, wherein the crystalline form is Form B, and wherein the XRPD pattern has peaks (± 0.2 degrees 2θ) at 11.8*0*, 9.3*0*, and 19.9.

9. The crystalline form of claim 7, wherein the crystalline form is Form B, and wherein the XRPD pattern has peaks (± 0.2 degrees 2θ) at 11.8, 9.3, 19.9, and 22.9.

10. The crystalline form of claim 7, wherein the crystalline form is Form B, and wherein the XRPD pattern has peaks (±0.2 degrees 2θ) at 11.8, 9.3, 19.9, 22.9, 17.2, 10.2, 20.4, 21.3, and 14.2.

11. The crystalline form of claim 7, wherein the crystalline form is Form B, and wherein Form B comprises water in an amount from 0% to 2.7% w/w.

12. The crystalline form of any one of claims 7-11, wherein the crystalline form is Form B having a TGA curve characterized by a weight loss of about 1.9% to about 2.0% at 100 $^{o}$C when heated from 30°C and 300°C at 10 K/min.

13. The crystalline form of any one of claims 7-11, wherein the crystalline form is Form B having a DSC thermogram characterized by a broad endotherm at $T_{onset}$ = 29.8° C and $T_{peak}$ = 65° C when heated from 30 and 300°C at a rate of 10 K/min.

14. The crystalline form of any one of claims 7-11, wherein the crystalline form is Form B absorbing up to 2.7% of moisture at 95 % RH at 25 °C by dynamic vapor sorption (DVS).

15. A pharmaceutical composition comprising the crystalline form of any one of claims 1-14 and a pharmaceutically acceptable carrier.

16. Use of the crystalline form of any one of claims 1-14, or the pharmaceutical composition of claim 15 in the manufacture of a medicament for the treatment of a disease or disorder associated with complement factor B (CFB), wherein an effective amount of the medicament is to be administered to a subject having such disease or disorder.

17. The method or use of claim 16 wherein the disease or disorder associated with complement factor B (CFB) is selected from the group consisting of: age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate

uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, glaucoma, Doyne honeycomb retinal dystrophy/Malattia leventinese, Sorsby fundus dystrophy, Late onset retinal macular dystrophy, North Carolina macular dystrophy, Stargardt disease, corneal inflammation, multiple sclerosis, stroke, Guillain Barré Syndrome, spinal cord injury, traumatic brain injury, Parkinson's disease, Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis (ALS), Huntington's disease, multifocal motor neuropathy, autism spectrum disorders, schizophrenia, drug-induced neurotoxicity, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis (including dense deposit disease and C3 glomerulonephritis), immune complex membranoproliferative glomerulonephritis (IC-MPGN), IgA nephropathy, membranous nephropathy including idiopathic membranous nephropathy, diabetic nephropathy, atypical hemolytic uremic syndrome (aHUS), Hemolytic uremic syndrome, STEC-HUS (Shiga toxin–producing Escherichia coli hemolytic uremic syndrome), peridontitis, CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, protein-losing enteropathy (CHAPLE syndrome), Crohn's disease, neuromyelitis optica (NMO), IgA vasculitis (formerly known as Henoch-Schönlein purpura or HSP), hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), adult respiratory distress syndrome (ARDS,), myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, acute kidney injury mesenteric artery reperfusion after aortic reconstruction, COVID-19, rheumatoid arthritis, osteoarthritis, Spondyloarthropathies, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, SLE nephritis, proliferative nephritis, myasthenia gravis, liver fibrosis, hemolytic anemia, tissue regeneration, neural regeneration, dyspnea, hemoptysis, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), Buerger's vasculitis, cryoglobulinemia, Kawasaki disease, Takayasu arteritis,

cryoglobulinemia, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity, immune thrombocytopenia, Cold agglutinin disease, Warm autoimmune hemolytic anemia (wAIHA), thrombotic thrombocytopenic purpura (TTP), abdominal aortic aneurisms, Grave's disease, and hidradenitis suppurativa.

18. The crystalline form of any one of claims 1-14, or the pharmaceutical composition of claim 15 for use in therapy.